MedTrace Logo

Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1

NCT01586052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2014-04-08

No results posted yet for this study

Summary

This purpose of this phase 1 study is to investigate the safety and efficacy of erythropoetin for children with cerebral palsy.

Conditions

  • Cerebral Palsy

Interventions

DRUG

Erythropoietin

250 IU/kg, Twice a week for 4 weeks

Sponsors & Collaborators

  • LG Life Sciences

    collaborator INDUSTRY

  • MinYoung Kim, M.D.

    lead OTHER

Principal Investigators

  • Minyoung Kim, M.D., Ph.D. · CHA University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586052 on ClinicalTrials.gov